KOMPLİKE OLMAYAN SELÜLİT VAKALARINDA FARKLI TEDAVİ SEÇENEKLERİNİN DEĞERLENDİRİLMESİ

Amaç: Günlük pratiğimizde sıklıkla karşılaştığımız selülit vakalarında kullanımı önerilmekte olan seftriaksonun, yarı ömrünün uzun olması nedeni ile kılavuzlarda günde tek doz olarak kullanılabileceği belirtilmekle birlikte zaman zaman tedavide sorunlar ile karşılaşabilmekteyiz. Bu nedenle günde tek doz seftriakson tedavisinin etkinliğinin diğer ajanlarla karşılaştırılarak değerlendirilmesi amaçlandı.

Anahtar Kelimeler:

Selülit, Seftriakson, Sefazolin

Evaluation of Different Treatment Options in Non-Complicated Cellulite Cases

Objective: Ceftriaxone is recommended for use in cellulite cases. It is indicated that its half-life is long and that it can be used as a single dose per day. However, we sometimes encounter problems in treatment. For this reason, the efficacy of once-dose ceftriaxone treatment was evaluated by comparing with other agents.

Keywords:

Ceftriaxone, Cefazolin, Cellulitis,

PDF

___

1. Raff AB, Kroshinsky D. Cellulitis: A Review. JAMA. 2016;316(3):325-37.
2. Lepak AJ, Andes DR. Cephalosporins. In: Bennet JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 9th ed. Philadelphia. Elsevier, 2019:268-84.
3. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL et al. Practice Guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis [Internet]. 2014;59(2):e10-52.
4. Sartelli M, Guirao X, Hardcastle TC, Kluger Y, Boermeester MA, Raşa K et al. 2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World J Emerg Surg. 2018;13:58. doi: 10.1186/s13017-018-0219-9.
5. Pasternack MS, Swartz MN. Cellulitis, necrotizing fasciitis, and subcutaneous tissue infections. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 9th ed. Philadelphia. Elsevier, 2019:1282-306.
6. Kim BN, Peri AM, Paterson DL. Ceftriaxon. In: Grayson ML, Cosgrove SE, Crowe SM, Hope W, Mccarthy JS, Mills J et al., eds. Kucers’ THE USE OF ANTIBIOTICS A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs. 7th ed. New York. CRC Press, Taylor and Francis Group, 2018:464-529.
7. Esposito S, Bassetti M, Concia E, De Simone G, De Rosa FG, Grossi P et al. Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. J Chemother [Internet]. 2017;29(4):197-214.
8. Morris A. Cellulitis and erysipelas. Clin Evid (Online). 2003;(10):1878-83.
9. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;(22):89-96.
10. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-12.
11. Gordin FM, Wofsy CB, Mills J. Once-daily ceftriaxone for skin and soft tissue infections. Antimicrob Agents Chemother. 1985;27(4):648-9.